Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
Public ClinicalTrials.gov record NCT06950385. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Patients With Familial Adenomatous Polyposis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to be answered by this trial are: * Does taking eRapa help to slow down the progression of the disease in patients with FAP? * Is eRapa a safe treatment for patients diagnosed with FAP? * What is the effect of eRapa on the number of polyps found in GI tract of patients diagnosed with FAP? * How does treatment with eRapa affect a patient's quality of life? Participants will: * Take eRapa or placebo once per day every other week until disease progresses (gets worse), stops taking part in the trial or dies. * Visit the clinic once every 3 months for check ups and tests. * Have an endoscopy at the start of the trial and then every 6 months to check on whether the disease is getting better or worse.
Study identification
- NCT ID
- NCT06950385
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 168 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 17, 2025
- Primary completion
- Jun 30, 2030
- Completion
- Dec 31, 2030
- Last update posted
- Jun 1, 2026
2025 – 2031
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Arcadia | California | 91007 | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06520 | Recruiting |
| Georgetown University | Washington D.C. | District of Columbia | 20057 | Recruiting |
| Digestive & Liver Center of Florida | Orlando | Florida | 32825 | Recruiting |
| Cleveland Clinic Florida | Weston | Florida | 33331 | Recruiting |
| University of Chicago | Chicago | Illinois | 60615 | Recruiting |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | Recruiting |
| Johns Hopkins University | Baltimore | Maryland | 21205 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | Recruiting |
| University of Michigan | Ann Arbor | Michigan | 48109 | Recruiting |
| Department of Surgery, Section of Colon Rectal and Surgery | St Louis | Missouri | 63110 | Recruiting |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Recruiting |
| Ohio State University | Columbus | Ohio | 43210 | Recruiting |
| Geisinger Medical Center | Danville | Pennsylvania | 17822 | Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Benaroya Research Institute at Virginia Mason | Seattle | Washington | 98101 | Recruiting |
| University of Washington - Fred Hutchinson | Seattle | Washington | 98195 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06950385, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 1, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06950385 live on ClinicalTrials.gov.